Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC.

Future oncology (London, England) - 1 Feb 2025

Heymach John V, Yu Helena A, Besse Benjamin, Cheng Ying, Tan Daniel Sw, Wei Li, Wacheck Volker, Nishio Makoto

Abstract excerpt

There remains a significant unmet need for effective and tolerable treatments for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in the first-line setting. First and later generation EGFR tyrosine kinase inhibitors (TKIs) have shown efficacy for common EGFR mutations; however, their effectiveness against ex20ins mutations is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Clinical Trials, Phase III as Topic

Share to ErbB Receptors

Share to Mutagenesis, Insertional

Share to Protein Kinase Inhibitors

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 39957151
DOI: 10.1080/14796694.2025.2457294
PMCID: PMC11845107

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC.PMID 39957151Read ↗

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectivesSemantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.Semantic proximity Read ↗

Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives.Semantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.Semantic proximity Read ↗

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion MutationsSemantic proximity Read ↗

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.Semantic proximity Read ↗

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialSemantic proximity Read ↗

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.